Information Provided By:
Fly News Breaks for October 14, 2019
LMAT
Oct 14, 2019 | 05:05 EDT
First Analysis analyst Joseph Munda upgraded LeMaitre to Strong Buy from Outperform with an unchanged price target of $37. The analyst views the company's acquisition of the CardioCel and VascuCel product lines positively. The acquired products lines are differentiated and expand LeMaitre's existing portfolio of biologic products, Munda tells investors in a research note. He cites the deal and valuation for his upgrade to Strong Buy.
News For LMAT From the Last 2 Days
There are no results for your query LMAT